USFDA warning letter for Monroe plant
Monroe facility received a warning letter, potentially delaying injectable product approvals and US growth acceleration.
GLENMARK / Q1-FY24 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
India acute segment slowdown
Slowdown in acute segments like respiratory and anti-infectives may pressure India growth, which is guided to single digits.
Debt and interest cost increase
Net debt at INR 2,947 crore and interest costs doubled YoY due to higher LIBOR, impacting profitability.
Glenmark Life Sciences stake sale uncertainty
Mandatory 7-8% stake sale in GLS by August 2024 may not significantly reduce debt as expected by some analysts.